View in EDS HTML Full Text PDF Full Text

A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.

Saved in:
Bibliographic Details
Title: A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.
Authors: Xicheng, Wang1 (AUTHOR), Yanhong, Deng2 (AUTHOR), Yanqiao, Zhang3 (AUTHOR), Tianshu, Liu4 (AUTHOR), Xianglin, Yuan5 (AUTHOR), Jianwei, Yang6 (AUTHOR), Tao, Zhang5 (AUTHOR), Aimin, Zang7 (AUTHOR), Yu, Liu8 (AUTHOR), Li, Huang9 (AUTHOR), Feng, Ye10 (AUTHOR), Hong, Zong11 (AUTHOR), Yi, Ba12 (AUTHOR), Isabelle, Klauck13 (AUTHOR), Jean‐Claude, Vedovato13 (AUTHOR), Mélanie, Groc13 (AUTHOR), Angela, Guo14 (AUTHOR), Jian, Li1 (AUTHOR) oncogene@163.com, Lin, Shen1 (AUTHOR)
Source: Cancer Medicine. Mar2026, Vol. 15 Issue 3, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.71697